After the Readout: How the Field Is Interpreting Compass' Phase 3 Psilocybin Data

Compass Pathways Phase 3 psilocybin data for treatment-resistant depression is being read as a likely path to FDA approval, even as efficacy is described as modest. Researchers and executives point to trial design elements and the availability of durability data, plus adverse event reporting focused on subjective drug effects, as key reasons the FDA hurdles may now be cleared compared to earlier setbacks. Commentators also weigh incremental clinical value such as the role of a second dose, debate how much psychological support reflects a safety baseline versus an efficacy ceiling, and consider what the move from individual trial sites to wider treatment networks could mean. Open questions remain about timing for regulatory decisions beyond the FDA and about competitive ripple effects in the psychedelics development landscape.